Related Experiment Video
Updated: Sep 9, 2025

Evidence-based Knowledge Synthesis and Hypothesis Validation: Navigating Biomedical Knowledge Bases via Explainable AI and Agentic Systems
Published on: June 13, 2025
Advancing drug-drug interactions research: integrating AI-powered prediction, vulnerable populations, and regulatory
Wenzhun Huang1,2, Xiao Wang3,4, Yunhao Chen1,2
1School of Electronic Information, Xijing University, Xi'an, Shaanxi, China.
Abstract:
Drug-drug interactions (DDIs) pose a significant and intricate challenge in clinical pharmacotherapy, especially among older adults who often have chronic conditions that necessitate multiple medications. These interactions can undermine the effectiveness of treatments or lead to adverse drug reactions (ADRs), which in turn can increase illness rates and strain healthcare resources. Traditional methods for detecting DDIs, such as clinical trials and spontaneous reporting systems, tend to be retrospective and frequently fall short in identifying rare, population-specific, or complex DDIs. However, recent advancements in artificial intelligence (AI), systems pharmacology, and real-world data analytics have paved the way for more proactive and integrated strategies for predicting DDIs. Innovative techniques like graph neural networks (GNNs), natural language processing, and knowledge graph modeling are being increasingly utilized in clinical decision support systems (CDSS) to improve the detection, interpretation, and prevention of DDIs across various patient demographics. This review aims to provide a thorough overview of the latest trends and future directions in DDIs research, structured around five main areas: (1) epidemiological trends and high-risk drug combinations, (2) mechanistic classification of DDIs, (3) methodologies for detection and prediction, particularly those driven by AI, (4) considerations for vulnerable populations, and (5) regulatory frameworks and pathways for innovation. Special emphasis is placed on the role of pharmacogenomic insights and real-world evidence in developing personalized strategies for assessing DDIs risks. By connecting fundamental pharmacological principles with advanced computational technologies, this review seeks to guide clinicians, researchers, and regulatory bodies. The integration of AI, multi-omics data, and digital health systems has the potential to significantly enhance the safety, accuracy, and scalability of DDIs management in contemporary healthcare.
Related Concept Videos
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Drug Discovery: Overview
Drug Regulation
Factors Affecting Drug Response: Overview
Analysis of Population Pharmacokinetic Data
Issues And Trends In Healthcare Delivery System
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...

